Literature DB >> 25645298

Tumor-infiltrating, interleukin-33-producing effector-memory CD8(+) T cells in resected hepatocellular carcinoma prolong patient survival.

Stefan M Brunner1, Christoph Rubner1, Rebecca Kesselring1, Maria Martin1, Eva Griesshammer1, Petra Ruemmele2, Thomas Stempfl3, Andreas Teufel4, Hans J Schlitt1, Stefan Fichtner-Feigl1,5.   

Abstract

UNLABELLED: Interleukin-33 (IL-33), a cytokine with pleiotropic functions, is elevated in serum of patients with hepatocellular carcinoma (HCC). This study investigated the effects of local IL-33 expression in resected HCC on patient survival and on the immunological and molecular tumor microenvironment. Tissue of resected HCCs was stained for hematoxylin and eosin, Masson trichrome, alpha-smooth muscle actin, IL-33, CD8, and IL-13 and analyzed by flow cytometry. Besides histomorphologic evaluation, the immunohistochemical stainings were analyzed for the respective cell numbers separately for tumor area, infiltrative margin, and distant liver stroma. These findings were correlated with clinical data and patient outcome. Further, gene expression of different HCC risk groups was compared using microarrays. In multivariable analysis, infiltration of HCCs by IL-33(+) cells (P = 0.032) and CD8(+) cells (P = 0.014) independently was associated with prolonged patient survival. Flow cytometry demonstrated that cytotoxically active subpopulations of CD8(+) cells, in particular CD8(+) CD62L(-) KLRG1(+) CD107a(+) effector-memory cells, are the main producers of IL-33 in these HCC patients. Using infiltration by IL-33(+) and CD8(+) cells as two separate factors, an HCC immune score was designed and evaluated that stratified patient survival (P = 0.0004). This HCC immune score identified high- and low-risk patients who differ in gene expression profiles (P < 0.001).
CONCLUSION: Infiltration of HCCs by IL-33(+) and CD8(+) cells is independently associated with prolonged patient survival. We suggest that this is due to an induction of highly effective, cytotoxically active CD8(+) CD62L(-) KLRG1(+) CD107a(+) effector-memory cells producing IL-33. Based on these two independent factors, we established an HCC immune score that provides risk stratification for HCC patients and can be used in the clinical setting.
© 2015 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25645298     DOI: 10.1002/hep.27728

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  41 in total

1.  Interleukin-33 Expression does not Correlate with Survival of Gastric Cancer Patients.

Authors:  Wenwei Hu; Xiaodong Li; Qing Li; Yan Tan; Bin Xu; Quanqin Xie; Xu Deng; Binfeng Lu; Jingting Jiang; Changping Wu
Journal:  Pathol Oncol Res       Date:  2016-12-20       Impact factor: 3.201

2.  Resection or Transplant in Early Hepatocellular Carcinoma.

Authors:  Markus B Schoenberg; Julian N Bucher; Adrian Vater; Alexandr V Bazhin; Jingcheng Hao; Markus O Guba; Martin K Angele; Jens Werner; Markus Rentsch
Journal:  Dtsch Arztebl Int       Date:  2017-08-07       Impact factor: 5.594

Review 3.  IL-33 in Tumor Immunity: Nothing to Sneeze At.

Authors:  Donye Dominguez; Yi Zhang; Bin Zhang
Journal:  Crit Rev Immunol       Date:  2018       Impact factor: 2.214

4.  Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody.

Authors:  Masahiro Morita; Naoshi Nishida; Kazuko Sakai; Tomoko Aoki; Hirokazu Chishina; Masahiro Takita; Hiroshi Ida; Satoru Hagiwara; Yasunori Minami; Kazuomi Ueshima; Kazuto Nishio; Yukari Kobayashi; Kazuhiro Kakimi; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2021-06-09       Impact factor: 11.740

5.  IL-33 activates mTORC1 and modulates glycolytic metabolism in CD8+ T cells.

Authors:  Yuejin Liang; Xiaofang Wang; Hui Wang; Wenjing Yang; Panpan Yi; Lynn Soong; Yingzi Cong; Jiyang Cai; Xuegong Fan; Jiaren Sun
Journal:  Immunology       Date:  2021-08-31       Impact factor: 7.215

6.  Highly differential count of circulating and tumor infiltrating immune cells in patients with non-HCV/non-HBV hepatocellular carcinoma.

Authors:  Markus Bo Schoenberg; Tong Zhu; Jingcheng Hao; Julian Nikolaus Bucher; Xiaokang Li; Xinyu Li; Yongsheng Han; Dionysios Koliogiannis; Michaela Svihla; Markus Otto Guba; Jens Werner; Alexandr V Bazhin
Journal:  Cancer Immunol Immunother       Date:  2021-09-28       Impact factor: 6.630

7.  Interleukin-33 and ST2 Signaling in Tumor Microenvironment.

Authors:  Jaewoo Hong; Soohyun Kim; P Charles Lin
Journal:  J Interferon Cytokine Res       Date:  2018-09-25       Impact factor: 2.607

8.  Pretreatment prediction of immunoscore in hepatocellular cancer: a radiomics-based clinical model based on Gd-EOB-DTPA-enhanced MRI imaging.

Authors:  Shuling Chen; Shiting Feng; Jingwei Wei; Fei Liu; Bin Li; Xin Li; Yang Hou; Dongsheng Gu; Mimi Tang; Han Xiao; Yingmei Jia; Sui Peng; Jie Tian; Ming Kuang
Journal:  Eur Radiol       Date:  2019-01-21       Impact factor: 5.315

9.  Chromosome 8p tumor suppressor genes SH2D4A and SORBS3 cooperate to inhibit interleukin-6 signaling in hepatocellular carcinoma.

Authors:  Carolin Ploeger; Nina Waldburger; Angelika Fraas; Benjamin Goeppert; Stefan Pusch; Kai Breuhahn; Xin Wei Wang; Peter Schirmacher; Stephanie Roessler
Journal:  Hepatology       Date:  2016-07-15       Impact factor: 17.425

Review 10.  Immunopathobiology and therapeutic targets related to cytokines in liver diseases.

Authors:  Yong He; Seonghwan Hwang; Yeni Ait Ahmed; Dechun Feng; Na Li; Marcelle Ribeiro; Fouad Lafdil; Tatiana Kisseleva; Gyongyi Szabo; Bin Gao
Journal:  Cell Mol Immunol       Date:  2020-11-17       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.